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In non-neuronal cells, glutamate is an extracellular signaling
mediator. Since podocytes have glutamate-containing
vesicles, we sought to determine glutamate receptor
presence and action in glomerular cells. The metabotropic
glutamate receptors (mGluR) 1, 5, 6, and 8 were found to be
expressed in mouse brain and glomeruli; predominantly in
podocytes. In two models of proteinuria (BalB/C mice with
puromycin aminonucleoside- and doxorubicin-induced
podocyte injury) we found that the selective mGluR1/5
agonist (S)-3,5-dihydroxyphenylglycine (DHPG) attenuated
albuminuria and improved the expression of the podocyte
marker WT-1. TUNEL staining showed that the number of
podocytes undergoing apoptosis was inversely correlated
with the number of WT-1–positive cells in glomeruli. When
podocytes were treated with DHPG in vitro, they generated
cyclic AMP and activated CREB (cyclic AMP response element
binding protein). The selective mGluR1/5 antagonist
(RS)-1-aminoindan-1,5-dicarboxylic acid, the adenylate
cyclase inhibitor SQ22536, and RNA interference knockdown
of mGluR1 or mGluR5 all prevented DHPG-induced cAMP
generation and CREB activation. DHPG inhibited apoptosis
and the decrease of aminonucleoside-induced mitochondrial
membrane potential in podocytes but had no effect in the
presence of SQ22536 with knockdown mGluR1 or mGluR5.
Thus, functional mGluR1 and mGluR5 are expressed in
podocytes and their activation protects against albuminuria
and podocyte apoptosis, processes that are, at least in part,
dependent on cAMP.
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Podocytes are highly differentiated cells with numerous foot
processes. The foot processes of neighboring podocytes
interdigitate sharing filtration slits bridged by the slit
diaphragm.1 Foot processes and their slit diaphragms
constitute an architectural element of the permeability
barrier.2 Previous researchers have shown that slit dia-
phragms and basal domains of foot processes are highly
dynamic signaling domains, and that intercellular signaling
has an important role in stability maintenance for foot
processes and the cytoskeleton.3,4 It is evident that podocytes
and neuron cells share a specialized cytoskeletal organization
and expression-restricted proteins.1,5 Rastaldi et al.6 demon-
strated that podocytes express the synaptic vesicle molecule
Rab3A and produce glutamate-containing vesicles. Sponta-
neous exocytosis of synaptic-like vesicles was observed
in cultured podocytes and in podocytes treated with
a-latrotoxin resulting in glutamate secretion,7 suggesting
that inter-foot processes and intercellular signaling can be
triggered in a glutamate-mediated synaptic-likemanner.
Glutamate is a major excitatory neurotransmitter in the
central nervous system. In non-neuronal cells, glutamate acts
as an extracellular signaling mediator.8 Glutamate receptors
are categorized into two major groups, ionotropic glutamate
receptors and metabotropic glutamate receptors (mGluRs).
Ionotropic glutamate receptors mediate fast excitatory
synaptic transmission and mGluRs influence a variety of
intracellular secondary messenger systems that modulate
synaptic stability and plasticity.9 mGluRs are all generally
expressed perisynaptically at presynaptic or postsynaptic sites
around ionotropic glutamate receptors. mGluRs are mem-
bers of the G-protein–coupled receptor family and also
regulate cellular responses independent of G-protein activa-
tion through interactions with other proteins including
scaffold proteins, cytoskeleton proteins, lipid raft proteins,
transmembrane proteins, and signaling proteins.
In this study, we provide evidence that mGluR1 and
mGluR5 genes and proteins are expressed by podocytes.
Activation of mGluR1/5 with (S)-3,5-dihydroxyphenylglycine
(DHPG) attenuated albuminuria induced by puromycin
aminonucleoside (PAN), or doxorubicin hydrochloride
(ADR), and podocyte apoptosis.
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RESULTS
mGluR1 and mGluR5 expression in mouse podocytes
mGluR1–8 mRNAs were expressed in BalB/C mouse brain
but only mGluR1, 5, 6, and 8 were found to be expressed in
differentiated podocytes (Figure 1a). BalB/C mouse brains,
isolated glomeruli, and differentiated and undifferentiated
podocytes produced mGluR 1, 5, 6, and 8 proteins (Figure
1b). We found that mGluR1 was located only in human
kidney glomeruli, whereas mGluR 5, 6, and 8 were located in
both glomeruli and tubular cells (Figure 1c). mGluR1 and
mGluR5 are both group I mGluRs and were detected in
podocytes, and thus we focused on the mGluR1 and mGluR5
in our subsequent research. The majority of mGluR1 found
in mice glomeruli was colocated with podocytes, as shown by
immunofluorescent double labeling with synaptopodin
(Figure 1d). Immunoelectron microscopy studies showed
that mGluR1 was found in the submembrane space of
podocyte bodies and foot processes (Figure 1e).
A group I mGluR agonist alleviated albuminuria induced by
PAN or ADR, and morphological changes in glomeruli
As shown in Figure 2a, PAN or ADR injection significantly
increased urinary albumin excretion. Urinary albumin in
control, PAN, and ADR groups was 2.02±0.06mg, 15.56±
3.74mg, and 25.81±6.64mg, respectively (Po0.01). In the
PANþDHPG and ADRþDHPG groups, urinary albumin
was 2.24±1.70mg and 9.23±4.80mg, respectively (com-
pared with respective PAN and ADR groups, Po0.01). In
comparison with the control group, the foot processes of
podocytes in the PAN- and ADR-treated mice were effaced,
retracted, and widened. These ultrastructural changes were
attenuated with DHPG treatment (Figure 2b and c). PAN or
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Figure 1 |mGluR1 and mGluR5 expression in mouse podocyte. (a) Reverse transcription-PCR was performed with normal BalB/C
mouse brain (Br) and differentiated murine podocytes (Po). (b) Western blot of brain (1), isolated glomeruli (2) from normal BalB/C mice,
and lysate from differentiated (3) and undifferentiated podocytes (4). (c) Immunofluorescence and immunohistochemical staining
of human kidney (original magnification  200). (d) Double staining of normal BalB/C mouse kidney (original magnification  400)
and brain (original magnification  20). White arrowhead: mGluR1 expression in hippocampus. (e) Immunoelectron microscopy
showing mGluR1 location in podocyte of BalB/C mice kidney, original magnification  46,000. mGluR, metabotropic glutamate
receptor.
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ADR injection was associated with a significant increase in
desmin production and reduction of nephrin expression.
DHPG administration reversed these changes (Figure 2d–f).
DHPG prevented podocyte loss associated with injury
induced by PAN and ADR
We calculated the average number of podocytes per
glomerulus with WT-1 staining. WT-1–positive cell numbers
per glomerulus were 3.24±0.23, 1.83±0.47, 3.12±0.59,
1.47±0.34, and 2.44±0.30 (Po0.05) for control, PAN,
PANþDHPG, ADR, and ADRþDHPG groups, respectively
(Figure 3a and b). As shown in Figure 3c and d, terminal
deoxytransferase uridine triphosphate nick end labeling
(TUNEL) and WT-1–positive cell numbers per 50 glomeruli
were 4.75±1.71, 78.00±21.18, 35.33±11.50, 89.44±12.76,
and 36.67±14.44, respectively (Po0.01). The TUNEL-
positive cell number was inversely associated with
WT-1–positive cell number, R2¼ 0.710, Po0.001 (Figure 3e).
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Figure 2 |DHPG alleviated kidney injury induced by PAN or ADR. (a) Twenty four-hour urine samples were collected for estimating
albuminuria. (b) Electron microscopy of a capillary loop (original magnification  13,500). (c) The width of foot process is shown in the bar
graph. (d) Histological appearance, desmin expression, and nephrin expression in glomeruli was assessed by light microscopy (PAS staining,
original magnification  400) and immunofluorescence staining, original magnification  400, respectively. (e) Western blot of kidney
cortex from mice. (f) Bar graph of data from at least five mice per group. *Po0.05 compared with control group. ADR, doxorubicin
hydrochloride; DHPG, (S)-3,5-dihydroxyphenylglycine; PAN, puromycin aminonucleoside; PAS, periodic acid–Schiff stain.
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DHPG alleviated apoptosis of podocytes induced
in vitro by PAN and ADR
As shown in Figure 4a, the podocyte number decreased to
25.54.±18.73 and 17.19±14.32%, after 48 h of incubation with
PAN and ADR, Po0.01. Pretreatment of podocytes with DHPG
alleviated cell loss induced by PAN and ADR (Figure 4a).
TUNEL staining showed that DHPG also attenuated apoptosis
induced by PAN and ADR, as shown in Figure 4b. Treatment of
podocytes with PAN resulted in cleaved caspase-3 upregulation
in a time-dependent manner (Figure 4c). Preincubation of
cells with DHPG reversed cleaved caspase-3 expression induced
by PAN (Figure 4d). We used JC-1 staining to show that
pretreatment with DHPG protected against mitochondrial
membrane potential decrease in podocytes induced by PAN.
In all, 14.43±4.30, 48.90±7.32, and 22.45±3.00% of podo-
cytes exhibited green fluorescence in control, PAN, and
PANþDHPG groups, respectively (Figure 4e and f).
DHPG activated cAMP signaling and [Ca2þ ]i influx in
podocytes
Cyclic adenosine 30,50 monophosphate (cAMP) generation
was detected in podocytes after 5min of incubation with
DHPG, but decreased after 15min (Figure 5a). DHPG
also enhanced DNA-binding activity to the cAMP response
element–binding protein (CREB) and phosphorylated
CREB expression after 30min of incubation, which remained
elevated until 60min (Figure 5b–d). As shown in Figure 5e,
the intracellular Ca2þ level was significantly increased
by continuous application of DHPG in 1.8mmol/l Ca2þ
solution, but not in a solution lacking Ca2þ . The intra-
cellular [Ca2þ ]i level was also increased by application of
2-aminoethoxydiphenylborane (IP3R inhibitor) with DHPG,
which suggested that DHPG-induced intracellular Ca2þ level
increase might be independent of IP3 signaling, and that
the extracellular Ca2þ influx contributed to the rise of the
Ca2þ level in podocytes (Figure 5f and g).
As shown in Figure 6a, e–g, both (RS)-1-aminoindan-1,
5-dicarboxylic acid and SQ22536 (an adenylate cyclase
inhibitor) prevented DHPG-induced cAMP generation and
CREB activation. However, 2-aminoethoxydiphenylborane
did not prevent these effects. Small interfering RNA (siRNA)
incubation resulted in downregulation of mGluR1 or
mGluR5 (Figure 6b). RNA interference knockdown of
mGluR1 and mGluR5 prevented DHPG-induced cAMP
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Figure 3 |DHPG prevented podocyte loss associated with injury induced by PAN and ADR. (a) Immunohistochemical staining was
performed to detect WT-1–positive cells in glomeruli (original magnification  400). The number of WT-1–positive cells were counted by
one renal pathologist using a blinded method. At least 50 glomeruli per kidney were calculated. Black arrow: WT-1–positive cells. (b) Shows
a bar graph of data expressed as average number per glomerulus. (c) TUNEL staining of different groups, original magnification  400. Both
TUNEL- and WT-1–positive cells were calculated by one renal pathologist using a blinded method. A total of 50 glomeruli per kidney were
calculated. White arrow: Both TUNEL and WT-1 staining of positive cells. Yellow arrow: TUNEL, but not WT-1–positive cells. (d) A bar graph of
data expressed as number per 50 glomeruli. (e) Linear correlation between WT-1–positive and TUNEL-positive cell numbers. *Po0.05
compared with control group, #Po0.05 compared with PAN or ADR group. ADR, doxorubicin hydrochloride; DAPI, 4,6-diamidino-2-
phenylindole; DHPG, (S)-3,5-dihydroxyphenylglycine; PAN, puromycin aminonucleoside; TUNEL, terminal deoxytransferase uridine
triphosphate nick end labeling.
Kidney International (2012) 81, 458–468 461
L Gu et al.: Functional mGluRs 1 and 5 expression in podocytes o r ig ina l a r t i c l e
generation and p-CREB expression (Figure 6c and d). Both
negative control siRNA and (RS)-a-methylserine-O-phos-
phate (a selective group III mGluRs antagonist) failed to
inhibit DHPG-induced cAMP production (Figure 6c).
cAMP signaling was involved in the protective effects of
DHPG
As shown in Figure 7a, both DHPG and an activator of
adenylate cyclase (forskolin) prevented the podocyte decrease
induced by PAN. DHPG lost the ability to protect against
podocyte loss induced by PAN in the presence of SQ22536.
Figure 7b and c showing JC-1 staining revealed that DHPG
and forskolin inhibited mitochondrial membrane potential
collapse induced by PAN, although these effects were retarded
by pretreatment with SQ22536. We used the CCK-8 test and
cleaved caspase-3 staining to find that mGluR1 or mGluR5
knockdown with RNA interference attenuated the protective
effects of DHPG (Figure 7d and e).
DISCUSSION
Podocytes form a tight network of interdigitating foot
processes, which are bridged by slit diaphragms.1 Slit
diaphragms represent the size selectivity of the filtration
barrier for proteins, but also mediate signal transduction in
podocytes.2–4 Slit diaphragm proteins, such as fyn, p85,
podocin, and FAT1 adaptor protein, contribute to the
regulation of cell polarity, podocyte survival, and reorganiza-
tion of the cytoskeleton.3,10,11 However, the communication
mechanism between podocytes that facilitates the response to
stimulation is poorly understood. Rastaldi et al.6 recently
described podocyte-specific expression of Rab3A and
rabphillin 3a, both of which have an important role in the
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Figure 4 |DHPG alleviated apoptosis of podocyte induced in vitro by PAN and ADR. (a) CCK-8 test performed using podocytes treated
with PAN (50mg/ml) or ADR (0.25 mg/ml) in the presence or absence of DHPG (50 mmol/l) for the time indicated. Data were obtained from
at least three independent studies. (b) Shows TUNEL staining results (original magnification  100). White arrows indicate the
TUNEL-positive cells. (c) Western blot of podocytes treated with PAN for the indicated time. (d) Western blots performed for podocytes
treated with PAN in the presence or absence of DHPG. (e, f) JC-1 staining and bar graph of data obtained from four to five independent
experiments. *Po0.05 compared with control; #Po0.05 compared with PAN group and $Po0.05 compared with ADR group. ADR,
doxorubicin hydrochloride; DHPG, (S)-3,5-dihydroxyphenylglycine; PAN, puromycin aminonucleoside; TUNEL, terminal deoxytransferase
uridine triphosphate nick end labeling.
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exocytosis of synaptic vesicles.12 Treatment with a-latotoxin
resulted in secretion of glutamate-containing vesicles by
podocytes.7 Furthermore, blocking of the ionotropic gluta-
mate receptors N-methyl-D-aspartate resulted in increased
albuminuria and rearrangement of the actin/myosin cyto-
skeleton.13 More recently, Puliti et al.14 developed mGluR1
gene mutation mice, which presented albuminuria and
podocyte foot process effacement. These data suggest that
the foot processes of podocytes might be specialized synapses,
where synaptic-like communications can be triggered bet-
ween podocytes and glutamatergic signaling might contri-
bute to the stabilization of the filtration barrier.
One open question regarding ‘synaptic view’ is the
identity of the presynaptic molecule in podocytes. mGluR1
was located in podocyte foot processes and cell bodies, which
suggests that glutamatergic signals might be transferred from
foot processes to cell bodies. Podocytes do not develop
distinct presynaptic structures, and thus communication
from foot processes to cell bodies may have a role in atypical
presynaptic signaling regulation. mGluR2, mGluR4, mGluR7,
and mGluR8 are located in the presynaptic membranes of
neurons and function in presynaptic regulation.9 We detected
mGluR8 gene and protein expression in podocytes. mGluR8
might thus have a role in presynaptic signaling regulation.
Mice are more resistant to PAN than rats,15 but we showed
that injection of male mice with 100mg/kg PAN induced a
significant podocyte injury. PAN injection in male mice led
to an increase in albuminuria and foot process width,
accompanied by upregulation of desmin and downregulation
of nephrin expression in podocytes. Our results agree with
those of Awad et al.16 Awad et al.16 demonstrated that
injection of mice with 100mg/kg PAN resulted in urinary
albumin excretion increase with foot process effacement, and
a reduction in podocin and ZO-1 gene expression.
Loss of podocytes correlates with progressive glomerulo-
sclerosis and in diabetic nephropathy, an ADR animal model
and a PAN-nephrosis model.17–19 Podocyte depletion can
occur as a result of podocyte necrosis, apoptosis, or
detachment.20 We found that the number of TUNEL-positive
cells was inversely associated with podocyte number, and we
suggest that apoptosis is an important cause of podocyte
depletion. We also found that PAN induced desmin
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expression in podocytes, which suggests that the podocyte
phenotype might be modified, thereby causing indirect
podocyte loss. Several agonists of receptor agonists such as
glucocorticoids, 1,25-OH2-vitamin D3, and darbepoetin are
known to prevent apoptosis of podocytes,21–23 which suggests
that exogenous signaling modulates the response of podo-
cytes. We found that activation of mGluR1/5 with DHPG
prevented podocyte apoptosis in mice and cells treated with
PAN or ADR, indicating that intercellular communication
may have an important role in podocyte response during
injury signaling. Antiapoptosis effects after activation of
group I mGluR are also known in neuronal cells, endothelial
cells, and T cells.24–26 In DHPG-treated neurons, the proline-
rich sequence in the C terminal of mGluR1/5 binds to EVH1
domain of Homer proteins enhancing formation of an
mGluR1/5-Homer protein-phosphoinositide 3-kinase enhan-
cer complex, leading to the activation of phosphatidylinositol
3-kinase activity and prevention of neuronal apoptosis.27,28
However, Homer proteins are constitutively expressed in the
central nervous system.9 Therefore, we investigated the role
of cAMP, which is another secondary message molecule
associated with G-protein–coupled receptors.
Intracellular cAMP in podocytes may regulate aspects of
podocyte behavior, including actin rearrangement, the
angiotensin II-activated Ca2þ pathway, and proliferation/
differentiation.29–31 Intracellular cAMP level is controlled by
adenylate cyclase and phosphodiesterases, which mediate the
degradation of cAMP.32 We found that an adenylate cyclase
inhibitor abolished DHPG-induced cAMP increase, suggest-
ing that treatment of podocytes with DHPG results in the
activation of adenylate cyclase, and that DHPG protection
against apoptosis in podocytes induced by PAN is at
least partially dependent on cAMP signaling pathway.
Liu et al.31 found that cAMP/CREB signaling promotes gene
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transcription of mitogen-activated protein kinase phos-
phatase-1 and production of protein in podocytes. Mito-
gen-activated protein kinase phosphatase-1 mediates the
anti-inflammatory effects of dexamethasone through inhibi-
tion of p38 phosphorylation,33 which has a role in podocyte
injury induced by PAN, diabetes, and TGF-b.34–36 Therefore,
DHPG-induced cAMP generation alleviates podocyte injury
induced by PAN via prevention of p38 phosphylation. Other
effects of cAMP on podocytes may include increased break-
down of angiotensin II and suppression of reactive oxygen
species generation.37 We found that adenylate cyclase
activation with forskolin directly protected against podocyte
decrease induced by PAN and mitochondrial membrane
potential collapse. Our study suggests that agents that
promote cAMP generation may provide protection for
podocytes.
Activation of mGluR1 with DHPG resulted in an
increased [Ca2þ ]i level in podocytes, suggesting that the
calcium signaling pathway may be activated. Increased
calcium influx mediates angiotensin II-induced podocyte
injury, and decreased cytosolic Ca2þ is associated with
podocyte survival.30,38,39 However, we were unable to identify
a proapoptotic role for DHPG. Thus, further work is required
to clarify the effects of intracellular [Ca2þ ] level increase and
the importance of DHPG-induced calcium influx.
We identified two shortcomings in the present study.
First, we did not separate the role of mGluR1 and mGluR5 in
DHPG-treated mice. Group I mGluR signal transduction is
mostly dependent on both mGluR1 and mGluR5 activation
in neuron cells.9 We found that siRNA knockdown of
mGluR1 or mGluR5 prevented DHPG-induced cAMP
generation and PAN-induced cell decrease in vitro, suggesting
that both mGluR1 and mGluR5 have important roles.
Second, some antagonists used in our experiments may have
been unsuited to determination of the function of specific
molecules, especially in high concentration. We treated
podocytes with the medium concentration, but we were
unable to eliminate this bias from these agents.
In summary, we found that functional mGluR1 and
mGluR5 were expressed in murine podocytes. Activation of
mGluR1 and mGluR5 with DHPG protected against
albuminuria induced by PAN or ADR and apoptosis of
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Figure 7 | cAMP signaling was involved in the protective effects of DHPG. (a) CCK-8 tests were performed using 50 mg/ml PAN-treated
podocytes in the presence or absence of DHPG (50 mmol/l) or forskolin (5 mmol/l). In one group, cells were preincubated with SQ22536
(200mmol/l) before DHPG treatment. Data were from four independent studies. (b, c) Showed JC-1 staining and bar graph of data obtained
from five independent experiments. (d) Different siRNA-treated podocytes, CCK-8 test of PAN-treated cells in the presence or absence
of DHPG. Data were from four independent studies. (e) Immunofluorescence staining to detect cleaved caspase-3 expression in wild-type
or siRNA-treated podocytes incubated with PAN and DHPG, original magnification  200. *Po0.05 compared with control; #Po0.05
compared with PAN group. cAMP, cyclic adenosine 30,50 monophosphate; DHPG, (S)-3,5-dihydroxyphenylglycine; mGluR, metabotropic
glutamate receptor; PAN, puromycin aminonucleoside; RNAi, RNA interference; siRNA, small interfering RNA.
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podocytes, via a pathway that was at least partially dependent
on cAMP signaling.
MATERIALS AND METHODS
Reagents
DHPG, (RS)-1-aminoindan-1,5-dicarboxylic acid, SQ22536, 2-amino-
ethoxydiphenylborane, (RS)-a-methylserine-O-phosphate, and for-
skolin were purchased from Tocris (Bristol, UK). PAN was purchased
from Sigma Chemical (St Louis, MO). ADR was purchased from
Enzo Life Sciences (Lausen, Switzerland). Stealth RNAi and
Lipofectamine 2000 transfection reagent were purchased from
Invitrogen (Carlsbad, CA).
Human tissue samples
We used nontumor tissues of the kidney from patients who had
renal cell carcinoma and who underwent nephrectomy. The study
was conducted under informed consent and was approved by the
ethics committee on human research of Renji Hospital, Shanghai
Jiaotong University School of Medicine.
Animal experiments
All animal procedures performed were approved by Shanghai
Jiaotong University School of Medicine. Male BalB/C mice
(Shanghai Slac Laboratory Animal, China) aged 8–10 weeks were
divided into control, PAN model, and DHPG-treated PAN model
groups. PAN nephrosis was induced by a single intravenous
injection of PAN 100mg/kg.16 In DHPG group, 1 mmol DHPG
was injected intravenously 1 h before the PAN injection. On day 6,
urine was collected for 24 h using a metabolic cage (n¼ 4–6 per
group). On the following day, mice were killed under chloral hydrate
anesthesia.
We induced mouse ADR nephropathy using 6-week-old male
BalB/C mice that received an intravenous injection of 10mg/kg body
weight doxorubicin hydrochloride.40 Administration of DHPG was
performed by intravenous injection at a dose of 1 mmol before
doxorubicin hydrochloride injection on days 1 and 7. On day 14,
urine was collected for 24 h using a metabolic cage (n¼ 9 per
group). On day 15, mice were killed under chloral hydrate
anesthesia. Kidneys were removed for analyses.
Transmission electron microscopy and immunoelectron
microscopy
Cortical kidney sections were fixed with 2.5% glutaraldehyde in 4 1C
phosphate-buffered saline overnight, postfixed in 1.0% OsO4, and
embedded in LR White resin (London Resin, Hampshire, England).
Ultrathin sections (70 nm) were stained with uranyl acetate and
examined under an electron microscope (Philips CM120; Eindho-
ven, The Netherlands) at 75 kV. One pathologist calculated the
width of the foot processes, at least 10 capillary loops per mice,
using the iTEM software (Olympus Soft Imaging Solutions GmbH,
Munster, Germany) with a blinded method.
For immunoelectron microscopy, kidneys were perfused through
the heart with 4% paraformaldehyde/2.5% glutaraldehyde in 4 1C
phosphate-buffered saline for 20min. Cortical kidney sections were
cut and dipped in 4% paraformaldehyde/2.5% glutaraldehyde
for 1 h. Sections were embedded in LR White resin and ultrathin
sections were prepared. Ultrathin sections were incubated with the
rabbit anti-mGluR1 antibody (1:500) overnight at 4 1C and 10 nm
gold conjugate (1:50). An electron microscope (Philips CM120) was
used for examination of sections.
Cell culture of podocytes
Conditionally immortalized mouse podocytes were a gift from
Dr Peter Mundel and have been described previously.41 The majority
of cells used in the present studies had an arborous shape and
expressed synaptopodin. Differentiated podocytes were cultured in
RPMI1640 without L-glutamine for 12–18 h. The cells were then
treated with various reagents. All experiments were repeated at least
four times for each indicated condition. Podocytes between passages
14 and 20 were used in all experiments.
RNA preparation and reverse transcription-PCR
Total RNA was isolated from podocytes, kidney, and brain using
Trizol reagent (Invitrogen, Grand Island, NY). After reverse
transcription, the product was denatured and amplified using a
GeneAmp PCR System 9600 (Perkin-Elmer, Norwalk, CT). The
primers are shown in Table 1. Conditions of one cycle at 94 1C for
2min, 40 cycles at 94 1C for 1min, 59 1C for 1min, 72 1C for 1min,
and 1 cycle at 72 1C for 5min were used for mGluR1–8. PCR
products were electrophoresed on 2% agarose gel containing
ethidium bromide.
RNA interference
Murine podocytes were seeded into six-well plates for 6 days. Cells
were transfected with 50 nmol/l of MSS274678 (SiRNA for mGluR1),
RSS302209 (siRNA for mGluR5), or 12935-400 (siRNA-negative
control) using Lipofectamine 2000 transfection reagent, following the
manufacturer’s instructions. Cells were analyzed for successful
MSS274678 or RSS302209 silencing 48 h after transfection.
Immunoblot analyses
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
immunoblot analyses were carried out according to standard
protocols and visualized using enhanced chemiluminescence
immunoblot detection kits (Amersham Pharmacia Biotech, Little
Chalfont, Buckinghamshire, UK). We used rabbit anti-human
Table 1 | The primer sequence of mGluR1–mGluR8
Genes Upstream (50–30) Downstream (50–30) Length (bp)
mGluR1 GGCCAATTTCAATGAGGCTA TCCGGAAAATGTTGAGGAAG 300
mGluR2 ATGCTCCCACAGCTATCACC TTGGCTTGGAAGAAGTCTGG 189
mGluR3 TATTCTCAGTCCTCTGCAAG TTGTAGCACATCACTACATACC 261
mGluR4 TCATTTTCTCTTCTGTTCCC GACATGCTACACATCAGAGAC 340
mGluR5 CCCCAAACTCTCCAGTCT ATTTTTCACCTCGGGTTC 210
mGluR6 GTGCCCAAAACCTACGTCAT AGCGTGGATCATGGTTTAGC 300
mGluR7 GAACTCTGTGAAAATGTAGACC TTAGGGAGTCCAGAATTACAG 321
mGluR8 CGAGGGTTATAACTACCAGGT TAGGTGCTGTGACAGATTTCT 440
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mGluR1a antibody (1:50), rabbit anti-human p-CREB antibody
(1:50) and rabbit anti-human CREB antibody (1:200, Santa Cruz,
CA), rabbit anti-human mGluR5 antibody (1:100), rabbit anti-
human mGluR8 (1:200, Abcam, Cambridge, UK), rabbit anti-
human murine mGluR6 (1:500, Novus Biologicals, LLC. Littleton,
CO), rabbit anti-human Caspase-3 (1:500), rabbit anti-human
cleaved caspase3 (1:200, Cell Signaling Technology, Danvers, MA),
and guinea-pig anti-mouse nephrin (1:500, Progen Biotechnik,
Heidelberg, Germany).
Immunofluorescence and immunohistochemical staining
Cryosections were prepared at 3-mm thickness using a cryostat,
and were fixed in cold acetone for 10min at 20 1C. After
blocking, cryosections were incubated with primary antibodies. For
double labeling, slides were incubated with secondary primary
antibodies and subsequent recognition with fluorescein isothiocya-
nate-conjugated secondary antibodies (1:200, Molecular Probes,
Eugene, OR), or Cy3/TRITC-labeled secondary antibodies (1:250,
Jackson, Baltimore Pike, PA). Fluorescence images were recorded
using a Leica TCS SP5II confocal microscope (Leica Microsystems,
Buffalo Grave, IL). The following primary antibodies were used:
guinea-pig anti-mouse nephrin (1:50), mouse anti-mouse synaptopo-
din (1:200, Progen Biotechnik), rabbit anti-human p-CREB antibody
(1:25), rabbit anti-human mGluR1a antibody (1:100), rabbit anti-
human WT-1 (1:50, Santa Cruz), rabbit anti-human mGluR8 (1:50),
rabbit anti-mouse desmin antibody (1:100, Abcam), rabbit anti-
human murine mGluR6 (1:100, Novus Biologicals), and rabbit anti-
human cleaved caspase-3 (1:100, Cell Signaling Technology).
For immunohistochemistry, 3-mm-thick cryosections were
prepared in a cryostat and fixed in cold acetone. After blocking,
cryosections were incubated with primary antibodies to WT-1
(1:100, Santa Cruz), rabbit anti-human mGluR5 antibody (1:50,
Abcam). Sections were then incubated with horseradish peroxidase-
labeled secondary antibodies (DAKO, Carpinteria, CA).
Enzyme immunoassay and enzyme-linked immunosorbent
assay
cAMP was measured in podocytes using a commercial solid-phase
quantitative competitive EIA kit for cAMP (Cayman Chemical, Ann
Arbor, MI), according to the manufacturer’s descriptions. The EIA
kit is sensitive to 0.1 pmol/ml. The cAMP content measured by EIA
was normalized to the total protein content.
Albuminuria was measured using a commercial ELISA kit
for murine albuminuria (Debo Biotechnology, Shanghai, China),
according to the manual description. Antibody for murine albumin
was purchased from Bethyl Laboratories (Montgomery, TX). In
brief, we added diluted standards of diluted mice urine to 96-well
plates. Anti-albumin antibody was added after incubation for
1 h. After incubation, we added horseradish peroxidase solution
and incubated the plates. The absorbance was read at 450 nm after
incubation with 3,30,5,50-tetramethyl benzidine substrate solution.
The sensitivity of this kit is 0.1 mg/ml.
Electrophoretic mobility shift assay
Nuclear extracts were prepared using a kit (Beyotime, Jiangsu,
China). The biotin-labeled double-stranded oligonucleotides used
commercially available consensus CREB gel shift oligonucleotide
50-biotin-AGAGATTGCCTGACGTCAGAGAGCTAG-30. Binding ac-
tivity of CREB to the probe was determined using a chemilumines-
cent EMSA kit (Beyotime).
Cell viability
Quantitative evaluation of cell viability was performed using a cell
count kit-8 (Beyotime), according to the manufacturer’s instruction.
The absorbance at 450 and 630 nm was determined using a
microplate reader.
Ca2þ imaging
Differentiated podocytes were loaded with 5 mmol/l of Flue4-AM
(Molecular Probes) for 15min at 37 1C, and then de-esterification of
the dye was allowed for another 15min.42 Subsequently, cells were
perfused in a calcium solution (1.8mmol/l Ca2þ ) or in Ca2þ -free
solution (0 Ca2þ ) for 2min, and then cells were incubated with
100 mmol/l DHPG with (n¼ 47 and 53 in calcium solution and
calcium-free group, respectively) or without 20mmol/l 2-amino-
ethoxydiphenylborane (n¼ 65 and 54, respectively). DMSO
in 1.8mmol/l Ca2þ solution (n¼ 23) or 0mol/l Ca2þ solution
(n¼ 25) was used as control. Ca2þ imaging was performed using a
Leica TCS SP5II confocal microscope with appropriate fluorescence
filters at room temperature. Data are expressed as F/F0, where F is
the absolute fluorescence value in an area of interest and F0 is
the resting fluorescence recorded under steady-state conditions.
Confocal whole-cell images were taken at a time interval of 2 s. The
Ca2þ imaging data were summarized as previously described.43
The control (1.8mmol/l Ca2þ ) solution was composed of the
following (in mmol/l): 140 NaCl, 5.4 KCl, 1.8 CaCl2, 1.0 MgCl2, 5.0
NaHCO3, 10.0 glucose, and 10 HEPES. The pH was adjusted to 7.4
with NaOH. In the Ca2þ -free (0 Ca2þ ) solution, CaCl2 was
omitted.
TUNEL staining
Cells that had entered advanced stages of apoptosis were detected
with a TUNEL assay, performed with a commercial fluorometric
TUNEL system kit (Promega, Madison, WI), according to the
manufacturer’s instructions. Fluorescently labeled sections were
counterstained with WT-1 staining and 4,6-diamidino-2-phenylin-
dole to visualize podocytes.
Determination of mitochondrial membrane potential
Mitochondrial membrane potential (DCm) was determined using
the dual emission mitochondrial dye 5,50,6,60-tetrachloro-1,10,3,30-
tetraethylbenzimidazolocarbocyanine iodide (JC-1, Beyotime). Low
DCm, the monomeric form of JC-1, fluoresces green (emission
B529 nm), whereas within the mitochondrial matrix, at high DCm,
JC-1 is able to form aggregates, which fluoresce red (emission
B590 nm). Mitochondrial membrane potential was quantified by
flow cytometric (BD FACS-Calibur, Franklin Lakes, NJ) determina-
tion of cells with green fluorescence.
Statistical analyses
All results are expressed as mean±s.d. Statistical analyses were
performed by SAS 6.04 (SAS Institute, Cary, NC). Analysis of
variance analyses with Duncan’s test and Dunnett’s test were used to
assess differences between multiple groups. Po0.05 was considered
as a statistically significant difference.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
This work was supported by the National Nature Science Foundation
Grant of China (30971363) and Nature Science Foundation Grant of
Kidney International (2012) 81, 458–468 467
L Gu et al.: Functional mGluRs 1 and 5 expression in podocytes o r ig ina l a r t i c l e
Shanghai (08ZR1413200) to LG, National Basic Research Program of
China 973 Program (2012CB517602) to ZN, Nature Science
Foundation Grant of Shanghai (10JC1410200) to YY as well as by a
grant (07JC14037) from the Nature Science Foundation of Shanghai
to JQ. We are grateful to Professor Peter Mundel (USA) and Professor
Yasuhiko Tomino (Japan) for the podocyte clones. We thank
Dr Xiaolong Cai and Jie Zhou for their calcium imaging studies. We
also appreciate Dr Lixing Chen for his ADR nephrosis mice model.
REFERENCES
1. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte.
Physiol Rev 2003; 83: 253–307.
2. Kawachi H, Miyauchi N, Suzuki K et al. Role of podocyte slit diaphragm as
a filtration barrier. Nephrology 2006; 11: 274–281.
3. Huber TB, Benzing T. The slit diaphragm: a signaling platform to regulate
podocyte function. Curr Opin Nephrol Hypertens 2005; 14: 211–216.
4. Mundel P, Shankland SJ. Podocyte biology and response to injury.
J Am Soc Nephrol 2002; 13: 3005–3015.
5. Weide T, Huber TB. Signaling at the slit: podocytes chat by synaptic
transmission. J Am Soc Nephrol 2009; 20: 1862–1864.
6. Rastaldi MP, Armelloni S, Berra S et al. Glomerular podocytes possess
the synaptic vesicle molecule Rab3A and its specific effector rabphillin-3a.
Am J Pathol 2003; 163: 889–899.
7. Rastaldi MP, Armelloni S, Berra S et al. Glomerular podocytes contain
neuron-like functional synaptic vesicles. FASEB J 2006; 20: 976–978.
8. Schoepp DD. Unveiling the functions of presynaptic metabotropic
glutamate receptors in the central nervous system. J Pharmacol Exp Ther
2001; 299: 12–20.
9. Enz R. The trick of the tail: protein-protein interactions of metabotropic
glutamate receptors. BioEssays 2007; 29: 60–73.
10. Zhu J, Sun N, Aoudjit L et al. Nephrin mediates actin reorganization via
phosphoinositide 3-kinase in podocytes. Kidney Int 2008; 73: 556–566.
11. Jones N, Blasutig IM, Eremina V et al. Nck adaptor proteins link nephrin to
the actin cytoskeleton of kidney podocytes. Nature 2006; 440: 818–823.
12. Giovedi S, Darchen F, Valtorta F et al. Synapsin is a novel Rab3 effector
protein on small synaptic vesicels. II. Functional effects of the Rab3A-
synapsin I interaction. J Biol Chem 2004; 279: 43769–43779.
13. Fukasawa H, Bornheimer S, Kudlicka K et al. Slit diaphragms contain tight
junction proteins. J Am Soc Nephrol 2009; 20: 1491–1503.
14. Puliti A, Rossi PI, Caridi G et al. Albuminuria and glomerular damage in
mice lacking the metabotropic glutamate receptor 1. Am J Pathol 2011;
178: 1257–1269.
15. Cheng ZZ, Patari A, Aalto-Setala K et al. Hypercholesterolemia is a
prerequisite for puromycin inducible damage in mouse kidney. Kidney Int
2003; 63: 107–112.
16. Awad AS, Rouse M, Liu L et al. Activation of adenosine 2A receptors
preserves structure and function of podocytes. J Am Soc Nephrol 2008;
19: 59–68.
17. Steffes MW, Schmidt D, McCrery R et al. Glomerular cell number in normal
subjects and in type 1 diabetic patients. Kidney Int 2001; 59: 2104–2113.
18. Marshall CB, Krofft RD, Pippin JW et al. The CDK-inhibitor p21 is pro-
survival in adriamycin (R)-induced podocyte injury, in vitro and in vivo.
Am J Physiol Renal Physiol 2010; 298: F1140–F1151.
19. Kanjanabuch T, Ma LJ, Chen J et al. PPAR-gamma agonist protects
podocytes from injury. Kidney Int 2007; 71: 1232–1239.
20. Wiggins RC. The spectrum of podocytopathies: a unifying view of
glomerular disease. Kidney Int 2007; 71: 1205–1241.
21. Wada T, Pippin JW, Marshall CB et al. Dexamethasone prevents podocyte
apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-
related family proteins. J Am Soc Nephrol 2005; 16: 2625.
22. Xiao H, Shi W, Liu S et al. 1,25-Dihydroxyvitamin D(3) prevents puromycin
aminonucleoside-induced apoptosis of glomerular podocytes by
activating the phosphatidylinositol 3-kinase/Akt-signaling pathway.
Am J Nephrol 2009; 30: 34–43.
23. Logar CM, Brinkkoetter PT, Krofft RD et al. Darbepoetin alfa protects
podocytes from apoptosis in vitro and in vivo. Kidney Int 2007; 72:
489–498.
24. Vincent AM, Maiese K. The metabotropic glutamate system promotes
neuronal survival through distinct pathways of programmed cell death.
Exp Neurol 2000; 166: 65–82.
25. Lin SH, Maiese K. Group I metabotropic glutamate receptors prevent
endothelial programmed cell death independent from MAP kinase p38
activation in rat. Neurosci Lett 2001; 298: 207–211.
26. Chioochetti A, Miglio G, Mesturini R et al. Group I mGlu receptor
stimulation inhibits activation-induced cell death of human
T lymphocytes. Br J Pharmacol 2006; 148: 760–768.
27. Tu JC, Xiao B, Yuan JP et al. Homer binds a novel proline-rich motif and
links group I metabotropic glutamate receptors with IP3 receptors.
Neuron 1998; 21: 717–726.
28. Rong R, Ahn JY, Huang H et al. PI3 kinase enhancer-Homer complex
couples mGluR1 to PI3 kinase, preventing neuronal apoptosis. Nat
Neurosci 2003; 6: 1153–1161.
29. Sharma R, Lovell HB, Wiegmann TB et al. Vasoactive substances
induce cytoskeletal changes in cultured rat glomerular epithelial cells.
J Am Soc Nephrol 1992; 3: 1131–1138.
30. Nitschke R, Henger A, Ricken S et al. Angiotensin II increases the
intracellular calcium activity in podocytes of the intact glomerulus.
Kidney Int 2000; 57: 41–49.
31. Liu TC, Wang Z, Feng X et al. Retinoic acid utilizes CREB and USF1 in a
transcriptional feed-forward loop in order to stimulate MKP1 expression
in human immunodeficiency virus-infected podocytes. Mol Cell Biol 2008;
28: 5785–5794.
32. Dousa TP. Cyclic-30 ,50-nucleotide phosphodiesterase isozymes in
cell bioloby and pathophysiology of the kidney. Kidney Int 1999;
55: 29–62.
33. Abraham SM, Lawrence T, Kleiman A et al. Antiinflammatory effects of
dexamethasone are parly dependent on induction of dual specificity
phosphatase 1. J Exp Med 2006; 203: 1883–1889.
34. Zheng CX, Chen ZH, Zeng CH et al. Triptolide protects podocytes from
puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int
2008; 74: 596–612.
35. Lim AK, Nikolic-Paterson DJ, Ma FY et al. Role of MKK3-P38 MAPK
signaling in the development of type 2 diabetes and renal injury in obese
db/db mice. Diabetologia 2009; 52: 347–358.
36. Jung KY, Chen K, Kretzler M et al. TGF-beta 1 regulates the PINCH-1-
integrin-linked kinases-alpha-parvin complex in glomerular cells. J Am Soc
Nephrol 2007; 18: 66–73.
37. Endlich N, Endlich K. cAMP pathway in podocytes. Microsc Res Tech 2002;
57: 228–231.
38. Henger A, Huber T, Fischer KG et al. Angiotensin II increases the
cytosolic calcium activity in rat podocytes in culture. Kidney Int 1997; 52:
687–693.
39. Foster RR, Hole R, Anderson K et al. Functional evidence that vascular
endothelial growth factor may act as an autocrine factor on human
podocytes. Am J Physiol Renal Physiol 2003; 284: f1263–f1273.
40. Koshikawa M, Mukoyama M, Mori K et al. Role of p38 Mitogen-Activated
Protein Kinase activation in podocyte injury and proteinuria in
experimental nephrotic syndrome. J Am Soc Nephrol 2005; 16: 2690–2701.
41. Mundel P, Reiser J, Kriz W. Induction of differentiation in cultured rat and
human podocytes. J Am Soc Nephrol 1997; 8: 697–705.
42. Kapur N, Mignery GA, Banach K. Cell cycle-dependent calcium oscillations
in mouse embryonic stem cells. Am J Physiol Cell Physiol 2007; 292:
C1510–C1518.
43. Tian D, Jacobo SM, Billing D et al. Antagonistic regulation of actin
dynamics and cell motility by TRPC5 and TRPC6 channels. Sci Signal 2010;
3: ra77.
468 Kidney International (2012) 81, 458–468
or ig ina l a r t i c l e L Gu et al.: Functional mGluRs 1 and 5 expression in podocytes
